

DAFTAR PUSTAKA

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: A report from the American Heart Association. *Circulation* 2013;127:e6-e245
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; 385:117-171
3. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. *Eur Heart J* 2014;35:2950-2959
4. Balitbang Kemenkes RI. 2013. Riset Kesehatan Dasar; RISKESDAS. Jakarta: Balitbang Kemenkes RI, hal 90-93
5. Thygesen K, Alpert JS, White HD, et al. Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551-2567
6. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013;34(38):2949-3003
7. Libby P. Inflammation in atherosclerosis. *Nature* 2002;420(6917):868-874
8. Schoenhagen P, Ziada KM, Kapadia SR, et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. *Circulation* 2000;101:598-603
9. Hansson GK. Mechanisms of disease: Inflammation, atherosclerosis and coronary artery disease. *N Engl J Med* 2005;352:1685-1695
10. Crea F, Liuzzo G. Pathogenesis of Acute Coronary Syndrome. *J Am Coll Cardiol* 2013;61:1-11
11. Libby P, Shi GP. Mast cells as mediators and modulators of atherogenesis. *Circulation* 2007;115:2471-2473
12. Mor A, Mekori YA. Mast cells and atherosclerosis. *IMAJ* 2001;3:216-221
13. Lindstedt KA, Mäyränpää MI, Kovanen PT. Mast cells in vulnerable atherosclerotic plaques - a view to a kill. *J Cell Mol Med* 2007;11(4):739-758
14. Bot I, Shi GP, Kovanen PT. Mast cells as effectors in atherosclerosis. *Arterioscler Thromb Vasc Biol* 2014;ATVBAHA.114.303570
15. Clejan S, Japa S, Clemetson C, et al. Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis. *J Cell Mol Med* 2002;6(4):583-592
16. Sayols-Baixeras S, Lluís-Ganella C, Lucas G, Elosua R. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. *The Application of Clinical Genetics* 2014;7:15-32
17. Hansson GK. Immune and inflammatory mechanisms in the development of atherosclerosis. *Br Heart J* 1993;69(Supplement):S38-S41
18. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: From pathophysiology to practice. *J Am Coll Cardiol* 2009;54:2129-2138

19. Kovanen PT. Mast cells: multipotent local effector cells in atherotrombosis. *Immunol Rev* 2007;217:105-22
20. Levick SP, Meléndez GC, Plante E, et al. Cardiac mast cells: The centrepiece in adverse myocardial remodelling. *Cardiovasc Resc* 2011;89:12-19
21. Bot I, dr Jager SC, Zerneck A, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. *Circulation* 2007;115:2516-2525
22. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. *Am J Pathol* 2003;163:1117-25
23. Caliguri G, Nikoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. *J Clin Invest* 2002;109:745-53
24. Boamponsem AG, Boamponsem LK. The role of inflammation in atherosclerosis. *Adv App. Sci Res* 2011, 2 (4):194-207
25. Young JL and Libby P. Atherosclerosis, In Lilly, L. S. Ed. Pathophysiology of heart disease: A collaborative project of medical student and faculty. Baltimore, *Lippincott Williams & Wilkins*, USA, 2007, PP 123, 132-138
26. Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. *Hypertens Res* 1995;18:87-98
27. Colwell J. Pathogenesis of vascular disease. *Diabetes Obes Metab* 2000;2(2):S19-S24
28. Libby P, Theroux P. Pathophysiology of coronary artery disease. *Circulation* 2005;111:3481-3488
29. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris of the European Society of Cardiology. *Eur Heart J* 2006;27:1341-1381
30. National Institutes of Health NH, Lung, and Blood Institute. Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute; 2012 PP 21-44
31. Ong P, Athanasiadis A, Borgulya G, et al. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries: The ACOVA Study (Abnormal COronary VAse motion inpatients with stable angina and unobstructed coronary arteries). *J Am Coll Cardiol* 2012;59:655-662
32. Amsterdam EA, Kirk JD, Blumke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. *Circulation* 2010;122:1756-1776
33. Lanza GA, Sestito A, Sgueglia GA, et al. Current clinical features, diagnostic assessment and prognostic determinants of patients with variant angina. *Int J Cardiol* 2007;118:41-47
34. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guidelines for the management of patients with non-ST-elevation Acute Coronary Syndrome: A report of the American College of Cardiology/American Heart

- Association Task Force on Practice Guidelines. *Circulation* 2014;130:e344-e426
35. Naik H, Sabatine MS, Lilly LS. Acute Coronary Syndrome In Lilly, L. S. Ed. Pathophysiology of heart disease: A collaborative project of medical student and faculty. Baltimore, *Lippincott Williams & Wilkins*, USA, 2007, PP 168-196
 36. Sasaguri Y, Tanimoto A. Role of macrophage-derived histamine in atherosclerosis: Chronic participation in the inflammatory response. *J Atheroscler Thromb* 2004;11:122-130
 37. Francis GS, Tang WHW. Histamine, mast cells and heart failure – Is there a connection? *J Am Coll Cardiol* 2006;48(7):1385-1386
 38. Vitorigo C, Giordano A, De Caprio L. Effects of histamine on coronary hemodynamics in humans: Role of H1 and H2 receptors. *J Am Coll Cardiol* 1987;10(6):1207-1213
 39. Satoh T, Sugama K, Matsuo A, et al. Histamine as an activator of cell growth and extracellular matrix reconstruction for human vascular smooth muscle cells. *Atherosclerosis* 1994;110:53-61
 40. Sasaguri Y, Tanimoto A. Extracellular matrix and matrix metalloproteinases in atherosclerosis. *Connective Tissue* 2002;34:327-336
 41. Jeannin P, Delneste P, Gosset S, et al. Histamine induced interleukin-8 secretion by endothelial cells. *Blood* 1994;84:2229-2233
 42. Delneste Y, Lassalle P, Jeannin P, et al. Histamine induces IL-6 production by human endothelial cells. *Clin Exp Immunol* 1994;98:344-349
 43. Li H, Burkhardt C, Heinrich UR, et al. Histamine upregulates gene expression of endothelial nitric oxide synthase in human vascular endothelial cells. *Circulation* 2003;107:2348-2354
 44. Jutel M, Klunker S, Akdis M, et al. Histamine upregulates Th1 and downregulates Th2 responses due to different patterns of surface histamine 1 and 2 receptor expression. *Int Arch Allergy Immunol* 2001;124:190-192
 45. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. *Nature* 2001;412:420-425
 46. Kritikou E, Kuiper J, Kovanen PT, Bot I. The impact of mast cells on cardiovascular diseases. *Eur J Pharmacol* 2015, <http://dx.doi.org/10.1016/j.ejphar.201504.050>
 47. Kaartinen M, Penttilä A, Kovanen PT. Mast cells of two types differing in neutral protease composition in the human aortic intima: Demonstration of tryptase and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of a thrombus. *Arterioscler Thromb* 1994;14:966-972
 48. Laine P, Kaartinen M, Penttilä A, et al. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. *Circulation* 1999;99:361-369
 49. Huang M, Pang X, Letourneau R, et al. Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in Apolipoprotein-E knockout mice. *Cardiovasc Research* 2002;55:150-160

50. Bot I, van Berkel TJC, Biessen EAL. Mast cells: Pivotal players in cardiovascular diseases. *Current Cardiology Reviews* 2008;4:170-178
51. Fahmida U, Wibowo Y, Ariawan I. 2008. Handbook Biostatistik 2: intermediate biostatistics for nutrition and health researchers. Jakarta: SEAMEO TROPMED RCCN. PP: 1-29;85-113
52. O'Donnell CJ, Elosua R. Cardiovascular risk factors: Insights from Framingham Heart Study. *Rev Esp Cardiol* 2008;61(3):299-310
53. Fox KA, Steg PG, Eagle KA, et al; GRACE Investigators. Decline in rates of death and heart failure in Acute Coronary Syndrome, 1999-2006. *JAMA* 2007;297:1892-1900
54. Mandelzweig L, Battler A, Boyko V, et al; Euro Heart Survey Investigators. The second Euro Heart Survey on Acute Coronary Syndrome: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. *Eur Heart J* 2006;27:2285-2293
55. Zdravkovic V, Pantovic S, Rosic G, et al. Histamine blood concentration in ischemic heart disease patients. *J Biomed Biotechnol* 2011 6;2011:315709
56. Campeau Lucien. Grading of angina pectoris. *Circulation* 1976;54:522-3
57. Wang KY, Tanimoto A, Guo X, et al. Histamine deficiency decrease atherosclerosis and inflammatory response in Apolipoprotein E knockout mice independently of serum cholesterol level. *Arterioscler Thromb Vasc Biol* 2011;31:800-807
58. Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders. *J Cell Mol Med* 2012;16(9):1978-1990